GlassScriptPhysician profile
Khosrow Alyeshmerni
NPI 1073534434
$9,579.09
in general payments reported to CMS, 2019-2025
43 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $1,182 · 2021: $1,512 · 2022: $1,932 · 2023: $1,205 · 2024: $986 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,792.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,114.51 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $948.61 | 2019-2024 | Lokelma, Farxiga |
| Abbvie INC. | $781.08 | 2019-2025 | Synthroid |
| Amgen INC. | $757.74 | 2019-2025 | Tepezza, Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $654.41 | 2019-2024 | |
| Amarin Pharma, INC. | $633.11 | 2019-2022 | |
| Lilly USA, LLC | $524.63 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.62 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $409.76 | 2022-2024 | |
| Amryt Pharma Holdings LTD | $365.11 | 2022-2023 | Mycapssa |
| Amneal Pharmaceuticals LLC | $233.73 | 2021-2024 | Unithroid |
| Xeris Pharmaceuticals, INC. | $228.39 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Chiesi USA, INC. | $191.60 | 2024 | Mycapssa |
| Abbott Laboratories | $183.93 | 2019-2023 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $169.02 | 2025 | Rezdiffra |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khosrow Alyeshmerni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.